Fumiya Moribe1, Momoko Nishikori1, Tsuyoshi Takashima2, Daiki Taniyama3, Nobuyuki Onishi4, Hiroshi Arima1, Hiroyuki Sasanuma5, Remi Akagawa5, Fathi Elloumi6, Shunichi Takeda5, Yves Pommier6, Eiichi Morii2, Akifumi Takaori-Kondo1, Junko Murai7. 1. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 2. Department of Pathology, Graduate School of Medicine, Osaka University, Osaka, Japan. 3. Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. 4. Division of Gene Regulation, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan. 5. Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 6. Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, United States of America. 7. Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan.
Abstract
BACKGROUND: SLFN11 has recently been reported to execute cancer cells harboring replicative stress induced by DNA damaging agents. However, the roles of SLFN11 under physiological conditions remain poorly understood. Germinal center B-cells (GCBs) undergo somatic hypermutations and class-switch recombination, which can cause physiological genotoxic stress. Hence, we tested whether SLFN11 expression needs to be suppressed in GCBs during B-cell development. OBJECTIVE: To clarify the expression profile of SLFN11 in different developmental stages of B-cells and B-cell-derived cancers. METHODS: We analyzed the expression of SLFN11 by mining cell line databases for different stages of normal B-cells and various types of B-cell-derived cancer cell lines. We performed dual immunohistochemical staining for SLFN11 and B-cell specific markers in normal human lymphatic tissues. We tested the effects of two epigenetic modifiers, an EZH2 inhibitor, tazemetostat (EPZ6438) and a histone deacetylase inhibitor, panobinostat (LBH589) on SLFN11 expression in GCB-derived lymphoma cell lines. We also examined the therapeutic efficacy of these drugs in combination with cytosine arabinoside and the effects of SLFN11 on the efficacy of cytosine arabinoside in SLFN11-overexpressing cells. RESULTS: SLFN11 mRNA level was found low in both normal GCBs and GCB-DLBCL (GCB like-diffuse large B-cell lymphoma). Immunohistochemical staining showed low SLFN11 expression in GCBs and high SLFN11 expression in plasmablasts and plasmacytes. The EZH2 and HDAC epigenetic modifiers upregulated SLFN11 expression in GCB-derived lymphoma cells and made them more susceptible to cytosine arabinoside. SLFN11 overexpression further sensitized GCB-derived lymphoma cells to cytosine arabinoside. CONCLUSIONS: The expression of SLFN11 is epigenetically suppressed in normal GCBs and GCB-derived lymphomas. GCB-derived lymphomas with low SLFN11 expression can be treated by the combination of epigenetic modifiers and cytosine arabinoside.
BACKGROUND:SLFN11 has recently been reported to execute cancer cells harboring replicative stress induced by DNA damaging agents. However, the roles of SLFN11 under physiological conditions remain poorly understood. Germinal center B-cells (GCBs) undergo somatic hypermutations and class-switch recombination, which can cause physiological genotoxic stress. Hence, we tested whether SLFN11 expression needs to be suppressed in GCBs during B-cell development. OBJECTIVE: To clarify the expression profile of SLFN11 in different developmental stages of B-cells and B-cell-derived cancers. METHODS: We analyzed the expression of SLFN11 by mining cell line databases for different stages of normal B-cells and various types of B-cell-derived cancer cell lines. We performed dual immunohistochemical staining for SLFN11 and B-cell specific markers in normal human lymphatic tissues. We tested the effects of two epigenetic modifiers, an EZH2 inhibitor, tazemetostat (EPZ6438) and a histone deacetylase inhibitor, panobinostat (LBH589) on SLFN11 expression in GCB-derived lymphoma cell lines. We also examined the therapeutic efficacy of these drugs in combination with cytosine arabinoside and the effects of SLFN11 on the efficacy of cytosine arabinoside in SLFN11-overexpressing cells. RESULTS:SLFN11 mRNA level was found low in both normal GCBs and GCB-DLBCL (GCB like-diffuse large B-cell lymphoma). Immunohistochemical staining showed low SLFN11 expression in GCBs and high SLFN11 expression in plasmablasts and plasmacytes. The EZH2 and HDAC epigenetic modifiers upregulated SLFN11 expression in GCB-derived lymphoma cells and made them more susceptible to cytosine arabinoside. SLFN11 overexpression further sensitized GCB-derived lymphoma cells to cytosine arabinoside. CONCLUSIONS: The expression of SLFN11 is epigenetically suppressed in normal GCBs and GCB-derived lymphomas. GCB-derived lymphomas with low SLFN11 expression can be treated by the combination of epigenetic modifiers and cytosine arabinoside.
Authors: Eric E Gardner; Benjamin H Lok; Valentina E Schneeberger; Patrice Desmeules; Linde A Miles; Paige K Arnold; Andy Ni; Inna Khodos; Elisa de Stanchina; Thuyen Nguyen; Julien Sage; John E Campbell; Scott Ribich; Natasha Rekhtman; Afshin Dowlati; Pierre P Massion; Charles M Rudin; John T Poirier Journal: Cancer Cell Date: 2017-02-13 Impact factor: 31.743
Authors: Federico Valdez; Julienne Salvador; Pedro M Palermo; Jonathon E Mohl; Kathryn A Hanley; Douglas Watts; Manuel Llano Journal: J Virol Date: 2019-07-17 Impact factor: 5.103
Authors: Rita Shaknovich; Leandro Cerchietti; Lucas Tsikitas; Matthias Kormaksson; Subhajyoti De; Maria E Figueroa; Gianna Ballon; Shao Ning Yang; Nils Weinhold; Mark Reimers; Thomas Clozel; Karin Luttrop; Tomas J Ekstrom; Jared Frank; Aparna Vasanthakumar; Lucy A Godley; Franziska Michor; Olivier Elemento; Ari Melnick Journal: Blood Date: 2011-08-09 Impact factor: 22.113
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113
Authors: Yasuhisa Murai; Ukhyun Jo; Naoko Takebe; Yves Pommier; Junko Murai; Lisa M Jenkins; Shar-Yin N Huang; Sirisha Chakka; Lu Chen; Ken Cheng; Shinsaku Fukuda Journal: Cancer Res Date: 2021-04-16 Impact factor: 13.312
Authors: Bingnan Zhang; Kavya Ramkumar; Robert John Cardnell; Carl Michael Gay; C Allison Stewart; Wei-Lien Wang; Junya Fujimoto; Ignacio I Wistuba; Lauren Averett Byers Journal: Br J Cancer Date: 2021-07-22 Impact factor: 9.075